Inmune Bio, Inc. current report, 30 September 2020

Abrir documento

Business Context and Reporting Period

Inmune Bio, Inc. (INMB), a Nevada corporation and emerging growth company, filed this Form 8-K to report the results of its Annual Meeting of Stockholders held on September 30, 2020. The company is headquartered in La Jolla, California, and its common stock trades on The NASDAQ Stock Market LLC.

Key Financial Metrics

This filing is a current report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.

Material Changes and Voting Results

The filing details the outcomes of two proposals submitted to stockholders:

  • Proposal One: Election of Directors. Stockholders elected all seven nominees to the Board of Directors. Notable voting statistics include:
    • Edgardo Baracchini, PhD: 5,663,584 votes for; 16,214 withheld.
    • J. Kelly Ganjei: 5,613,870 votes for; 65,928 withheld.
    • Scott Juda, JD: 5,663,185 votes for; 16,613 withheld.
    • Tim Schroeder: 5,268,118 votes for; 411,680 withheld (highest number of withheld votes).
    • David Szymkowski, PhD: 5,655,585 votes for; 24,213 withheld.
    • Raymond J. Tesi, MD: 5,656,289 votes for; 23,509 withheld.
    • Marcia Allen: 5,653,422 votes for; 26,376 withheld.
    • Broker Non-Votes: 3,285,842 shares were recorded as broker non-votes for all director nominees.
  • Proposal Two: Ratification of Independent Auditor. Stockholders approved the appointment of Marcum LLP as the independent auditor for the fiscal year ending December 31, 2020.
    • For: 8,921,491
    • Against: 23,643
    • Abstentions: 20,506
    • Broker Non-Votes: 0

Guidance, Outlook, and Risks

The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It is strictly a disclosure of the voting results from the annual meeting.

Investor Verification Checklist

  • Verify the total number of shares outstanding and the quorum status at the September 30, 2020 meeting to contextualize the vote counts.
  • Review the proxy statement (DEF 14A) filed prior to this meeting for detailed biographies of the elected directors and the rationale for the auditor appointment.
  • Check subsequent filings (10-Q or 10-K) for the company's actual financial performance, as this 8-K contains no financial data.
  • Monitor the tenure of the newly elected directors, as they serve until the next annual meeting.